Immune Suppressive Effects of Plasma-Derived Exosome Populations in Head and Neck Cancer.
HNSCC
immune regulation
liquid biopsy
tumor-derived exosomes
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
21 Jul 2020
21 Jul 2020
Historique:
received:
02
07
2020
revised:
17
07
2020
accepted:
18
07
2020
entrez:
26
7
2020
pubmed:
28
7
2020
medline:
28
7
2020
Statut:
epublish
Résumé
Plasma-derived exosomes of head and neck squamous cell carcinoma (HNSCC) patients carry inhibitory factors mediating immune suppression. Separation of tumor-derived exosomes (TEX) and non-TEX may assist in a better understanding of their respective parental cells. Here, we evaluate the impact of TEX or hematopoietic-derived exosomes on immune suppression. We evaluated apoptosis in CD8+ T cells, conversion of CD4+ T cells to regulatory T cells (T
Identifiants
pubmed: 32708274
pii: cancers12071997
doi: 10.3390/cancers12071997
pmc: PMC7409343
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Clin Cancer Res. 2002 Aug;8(8):2553-62
pubmed: 12171883
Expert Rev Mol Diagn. 2018 Dec;18(12):1029-1040
pubmed: 30406709
Br J Cancer. 2013 Nov 12;109(10):2629-35
pubmed: 24169351
Clin Cancer Res. 2018 Feb 15;24(4):896-905
pubmed: 29233903
Clin Cancer Res. 2006 Jul 1;12(13):3890-5
pubmed: 16818683
J Extracell Vesicles. 2016 Mar 24;5:29289
pubmed: 27018366
Clin Exp Immunol. 2014 Aug;177(2):531-43
pubmed: 24749746
J Cell Sci. 2013 Dec 15;126(Pt 24):5553-65
pubmed: 24105262
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
pubmed: 16344461
Adv Clin Chem. 2016;74:103-41
pubmed: 27117662
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Oncoimmunology. 2019 Apr 24;8(7):1593805
pubmed: 31143513
Cell Mol Neurobiol. 2016 Apr;36(3):301-12
pubmed: 27053351
Am J Pathol. 2014 Jan;184(1):28-41
pubmed: 24269592
Future Oncol. 2017 Dec;13(28):2583-2592
pubmed: 29198150
Oncoimmunology. 2020 Apr 7;9(1):1747732
pubmed: 32313730
Eur J Immunol. 2017 Jun;47(6):946-953
pubmed: 28475283
Cancer Res. 2012 May 1;72(9):2162-71
pubmed: 22549946
Clin Exp Immunol. 2017 Sep;189(3):259-267
pubmed: 28369805
J Immunol. 2011 Jul 15;187(2):676-83
pubmed: 21677139
J Clin Oncol. 2013 Mar 1;31(7):845-52
pubmed: 23182993
Neuro Oncol. 2016 Apr;18(4):497-506
pubmed: 26385614
N Engl J Med. 2005 Dec 22;353(25):2654-66
pubmed: 16371631
Oncoimmunology. 2016 Feb 26;5(2):e1082703
pubmed: 27057473
N Engl J Med. 2004 May 6;350(19):1937-44
pubmed: 15128893
Cancer Res. 2017 Dec 1;77(23):6480-6488
pubmed: 29162616
Clin Exp Immunol. 2018 Jun;192(3):271-283
pubmed: 29431869
Cancer Res. 2007 Sep 15;67(18):8865-73
pubmed: 17875728
Sci Rep. 2016 Feb 04;6:20254
pubmed: 26842680
Sci Rep. 2020 Jan 9;10(1):92
pubmed: 31919420
Clin Cancer Res. 2018 Jan 1;24(1):6-13
pubmed: 28751445
Clin Cancer Res. 2017 Aug 15;23(16):4843-4854
pubmed: 28400428
Immunol Lett. 2018 Apr;196:22-32
pubmed: 29366662
Clin Exp Immunol. 2018 Oct;194(1):67-78
pubmed: 30229863